SLC5A2 and atrial fibrillation: SGLT-2 inhibition decreases weight and fat mass, with reduction in body and epicardial fat, and lowers inflammation, fibrosis, ventricular mass, hypertrophy, and pressure, all of which reduce AF risk [30].